Shows & Panels
- AFCEA Answers
- Ask the CIO
- The Big Data Dilemma
- Carrying On with Continuity of Operations
- Connected Government
- Constituent Servicing
- Continuous Monitoring: Tools and Techniques for Trustworthy Government IT
- The Cyber Imperative
- Cyber Solutions for 2013 and Beyond
- The Data Privacy Imperative: Safeguarding Sensitive Data
- Expert Voices
- Federal Executive Forum
- Federal IT Challenge
- Federal Tech Talk
- Mission-critical Apps in the Cloud
- The Modern Federal Threat Landscape
- The Path from Legacy Systems
- The Real Deal on Digital Government
- The Reality of Continuous Monitoring... Is Your Agency Secure?
- Veterans in Private Sector: Making the Transition
Shows & Panels
FDA cracks down on unapproved painkillers
Thursday - 7/5/2012, 10:29am EDT
WASHINGTON (AP) - The Food and Drug Administration says it will begin cracking down on companies that market versions of the painkiller oxycodone which have not undergone federal review.
Oxycodone is a powerful pain reliever with the potential for addiction, abuse and death, when used inappropriately. The drug is marketed legally by companies like Purdue Pharma, which sells the time-release pill OxyContin. FDA reviews these drugs to make sure they are safe and effective.
However, other companies have marketed similar pills for years without FDA clearance.
In a federal register notice, the FDA said companies marketing unapproved versions of oxycodone have 45 days to cease manufacturing them. Companies that don't comply will be subject to product seizure and court proceedings.
Oxycodone and other opioid painkillers are among the most widely-abused drugs in the U.S.
(Copyright 2012 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.)